264 related articles for article (PubMed ID: 3132324)
41. [Comparative study of the activating effects of recombinant human interleukin 2 and interferon-gamma on cell-mediated cytotoxicity against renal cell carcinoma in vitro].
Marumo K; Ueno M; Baba S; Muraki J; Deguchi N; Tazaki H
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1825-9. PubMed ID: 3109327
[TBL] [Abstract][Full Text] [Related]
42. Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma.
Bajorin DF; Chapman PB; Wong G; Coit DG; Kunicka J; Dimaggio J; Cordon-Cardo C; Urmacher C; Dantes L; Templeton MA
Cancer Res; 1990 Dec; 50(23):7490-5. PubMed ID: 2253196
[TBL] [Abstract][Full Text] [Related]
43. Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study.
Atzpodien J; Körfer A; Evers P; Franks CR; Knüver-Hopf J; Lopez-Hänninen E; Fischer M; Mohr H; Dallmann I; Hadam M
Mol Biother; 1990 Mar; 2(1):18-26. PubMed ID: 2334534
[TBL] [Abstract][Full Text] [Related]
44. A direct comparison of immunological and clinical effects of interleukin 2 with and without interferon-alpha in humans.
Schiller JH; Hank J; Storer B; Borchert AA; Moore KH; Albertini M; Bechhofer R; Wesley O; Brown RR; Bastin AM
Cancer Res; 1993 Mar; 53(6):1286-92. PubMed ID: 8443808
[TBL] [Abstract][Full Text] [Related]
45. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.
Lotze MT; Matory YL; Ettinghausen SE; Rayner AA; Sharrow SO; Seipp CA; Custer MC; Rosenberg SA
J Immunol; 1985 Oct; 135(4):2865-75. PubMed ID: 2993418
[TBL] [Abstract][Full Text] [Related]
46. A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma.
Mittelman A; Huberman M; Puccio C; Fallon B; Tessitore J; Savona S; Eyre R; Gafney E; Wick M; Skelos A
Cancer; 1990 Aug; 66(4):664-9. PubMed ID: 2386896
[TBL] [Abstract][Full Text] [Related]
47. A phase I trial of recombinant interleukin-2 combined with recombinant interferon-gamma in patients with cancer.
Redman BG; Flaherty L; Chou TH; al-Katib A; Kraut M; Martino S; Chen B; Kaplan J; Valdivieso M
J Clin Oncol; 1990 Jul; 8(7):1269-76. PubMed ID: 2113571
[TBL] [Abstract][Full Text] [Related]
48. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.
Rosenberg SA; Lotze MT; Muul LM; Chang AE; Avis FP; Leitman S; Linehan WM; Robertson CN; Lee RE; Rubin JT
N Engl J Med; 1987 Apr; 316(15):889-97. PubMed ID: 3493432
[TBL] [Abstract][Full Text] [Related]
49. Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma.
Miller RL; Steis RG; Clark JW; Smith JW; Crum E; McKnight JE; Hawkins MJ; Jones MJ; Longo DL; Urba WJ
Cancer Res; 1989 Apr; 49(7):1871-6. PubMed ID: 2647294
[TBL] [Abstract][Full Text] [Related]
50. Recombinant interleukin-2 in combination with recombinant interferon-gamma in patients with advanced malignancy: a phase 1 study.
Reddy SP; Harwood RM; Moore DF; Grimm EA; Murray JL; Vadhan-Raj S
J Immunother; 1997 Jan; 20(1):79-87. PubMed ID: 9101417
[TBL] [Abstract][Full Text] [Related]
51. Natural cytotoxic activity in multiple sclerosis patients: defects in IL-2/interferon gamma-regulatory circuit.
Braakman E; van Tunen A; Meager A; Lucas CJ
Clin Exp Immunol; 1986 Nov; 66(2):285-94. PubMed ID: 2949897
[TBL] [Abstract][Full Text] [Related]
52. Phase I study of i.v. administered recombinant gamma interferon in cancer patients.
Kurzrock R; Quesada JR; Rosenblum MG; Sherwin SA; Gutterman JU
Cancer Treat Rep; 1986 Dec; 70(12):1357-64. PubMed ID: 3098417
[TBL] [Abstract][Full Text] [Related]
53. Renal cell carcinoma: treatment with recombinant interleukin-2 plus beta-interferon.
Krigel RL; Padavic-Shaller KA; Rudolph AR; Konrad M; Bradley EC; Comis RL
J Clin Oncol; 1990 Mar; 8(3):460-7. PubMed ID: 2407809
[TBL] [Abstract][Full Text] [Related]
54. Systemic administration of recombinant methionyl human interleukin-2 (Ala 125) to cancer patients: clinical results.
Sarna GP; Figlin RA; Pertcheck M; Altrock B; Kradjian SA
J Biol Response Mod; 1989 Feb; 8(1):16-24. PubMed ID: 2784163
[TBL] [Abstract][Full Text] [Related]
55. Transient decrease in IL-2-responsive lymphocytes 24 hours after initiation of continuous IL-2 infusion in cancer patients.
Weil-Hillman G; Hank JA; Rosenthal NS; Sondel PM
J Biol Response Mod; 1988 Oct; 7(5):424-37. PubMed ID: 3053997
[TBL] [Abstract][Full Text] [Related]
56. American cancer society Phase I trial of naturally produced beta-interferon.
Hawkins MJ; Krown SE; Borden EC; Krim M; Real FX; Edwards BS; Anderson SA; Cunningham-Rundles S; Oettgen HF
Cancer Res; 1984 Dec; 44(12 Pt 1):5934-8. PubMed ID: 6498851
[TBL] [Abstract][Full Text] [Related]
57. [In vitro enhancement of cytotoxicity of human peripheral blood lymphocytes with recombinant interleukin 2 and an interferon mixture (alpha + beta + gamma) against human colon carcinoma cell line SW1116].
Kimoto Y
Gan To Kagaku Ryoho; 1986 Dec; 13(12):3419-26. PubMed ID: 3098183
[TBL] [Abstract][Full Text] [Related]
58. Enhanced antitumor effect of combination therapy with interleukin-2 and polyribonucleotides against adenocarcinoma 755.
Iigo M; Nakajima Y; Nishikata K; Hoshi A
J Biol Response Mod; 1989 Apr; 8(2):147-54. PubMed ID: 2786554
[TBL] [Abstract][Full Text] [Related]
59. A phase I study of recombinant interferon-beta in patients with advanced malignant disease.
Ravandi F; Estrov Z; Kurzrock R; Breitmeyer JB; Maschek BJ; Talpaz M
Clin Cancer Res; 1999 Dec; 5(12):3990-8. PubMed ID: 10632330
[TBL] [Abstract][Full Text] [Related]
60. Phase I trial of recombinant interferon gamma by 1-hour i.v. infusion.
Vadhan-Raj S; Nathan CF; Sherwin SA; Oettgen HF; Krown SE
Cancer Treat Rep; 1986 May; 70(5):609-14. PubMed ID: 3085930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
